Literature DB >> 16926565

Parenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin Beta receptor expression.

Woodae Kang1, F Enrique Gomez, Jinggang Lan, Yoshifumi Sano, Chikara Ueno, Kenneth A Kudsk.   

Abstract

OBJECTIVE: To determine the effects of parenteral nutrition (PN) on LTbetaR in gut-associated lymphoid tissue (GALT), particularly the intestine and Peyer's patches (PP). SUMMARY BACKGROUND DATA: Lack of enteral stimulation with PN impairs mucosal immunity and reduces IgA levels through depression of GALT cytokines (IL-4 and IL-10) and GALT specific adhesion molecules. We have shown that each is critical to intact mucosal immunity through effects on lymphocyte homing, IgA production, and resistance to antibacterial and antiviral immunity. IgA is the principal specific immunologic mucosal defense. LTbetaR stimulation controls production of IL-4, the adhesion molecule MAdCAM-1, and other key components of GALT, all of which are important in increasing IgA levels and maintaining mucosal defenses.
METHODS: Experiment 1: LTbetaR expression in intestine and PP was analyzed by Western blot after 5 days of chow, a complex enteral diet (CED), or PN. Diets were isocaloric and isonitrogenous except for chow. Experiment 2: After completing pilot experiments to determine the appropriate dose of the LTbetaR agonistic antibody, mice received chow, PN + 5 mug of anti-LTbetaR mAb (2 times/d, i.v.) or PN + isotype control antibody. PP lymphocytes and intestinal IgA levels were measured after 2 days.
RESULTS: Lack of enteral stimulation with PN significantly decreased LTbetaR expression in intestine and PP compared with chow and CED. LTbetaR stimulation with an agonistic anti-LTbetaR mAb significantly increased PP lymphocyte counts and intestinal IgA in PN fed-mice.
CONCLUSIONS: LTbetaR expression is critical for GALT control mechanisms and intact mucosal immunity. PN reduces LTbetaR expression, PP lymphocytes, and intestinal IgA production. Exogenous LTbetaR stimulation reverses PN-induced depression of gut mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926565      PMCID: PMC1856545          DOI: 10.1097/01.sla.0000234797.42935.46

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  Route of nutrition influences generation of antibody-forming cells and initial defense to an active viral infection in the upper respiratory tract.

Authors:  Cheryl D Johnson; Kenneth A Kudsk; Kazuhiko Fukatsu; Kathryn B Renegar; Ben L Zarzaur
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 2.  Intestinal IgA synthesis: regulation of front-line body defences.

Authors:  Sidonia Fagarasan; Tasuku Honjo
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

Review 3.  Regulation of IgA synthesis at mucosal surfaces.

Authors:  Sidonia Fagarasan; Tasuku Honjo
Journal:  Curr Opin Immunol       Date:  2004-06       Impact factor: 7.486

Review 4.  Lymphotoxin/light, lymphoid microenvironments and autoimmune disease.

Authors:  Jennifer L Gommerman; Jeffrey L Browning
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

5.  TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression.

Authors:  K Fukatsu; K A Kudsk; B L Zarzaur; Y Wu; M K Hanna; R C DeWitt
Journal:  Shock       Date:  2001-04       Impact factor: 3.454

6.  Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Authors:  Jeffrey L Browning; Norm Allaire; Apinya Ngam-Ek; Evangelia Notidis; Jane Hunt; Steven Perrin; Roy A Fava
Journal:  Immunity       Date:  2005-11       Impact factor: 31.745

7.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways.

Authors:  Emmanuel Dejardin; Nathalie M Droin; Mireille Delhase; Elvira Haas; Yixue Cao; Constantin Makris; Zhi-Wei Li; Michael Karin; Carl F Ware; Douglas R Green
Journal:  Immunity       Date:  2002-10       Impact factor: 31.745

8.  Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity.

Authors:  K B Renegar; C D Johnson; R C Dewitt; B K King; J Li; K Fukatsu; K A Kudsk
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

9.  Elimination of colonic patches with lymphotoxin beta receptor-Ig prevents Th2 cell-type colitis.

Authors:  T Dohi; P D Rennert; K Fujihashi; H Kiyono; Y Shirai; Y I Kawamura; J L Browning; J R McGhee
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 10.  Lymphoid microenvironment in the gut for immunoglobulin A and inflammation.

Authors:  Robert Chin; Jing Wang; Yang-Xin Fu
Journal:  Immunol Rev       Date:  2003-10       Impact factor: 12.988

View more
  17 in total

1.  Epidermal growth factor/TNF-α transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral nutrition.

Authors:  Yongjia Feng; Daniel H Teitelbaum
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-10       Impact factor: 4.052

2.  Continuous enteral and parenteral feeding each reduces heart rate variability but differentially influences monocyte gene expression in humans.

Authors:  Stephen C Gale; Beth-Ann Shanker; Susette M Coyle; Marie A Macor; Chun W Choi; Steve E Calvano; Siobhan A Corbett; Stephen F Lowry
Journal:  Shock       Date:  2012-08       Impact factor: 3.454

Review 3.  The gastrointestinal immune system: Implications for the surgical patient.

Authors:  Joseph F Pierre; Rebecca A Busch; Kenneth A Kudsk
Journal:  Curr Probl Surg       Date:  2015-10-23       Impact factor: 1.909

4.  Jonathan E Rhoads lecture: Of mice and men... and a few hundred rats.

Authors:  Kenneth A Kudsk
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 Jul-Aug       Impact factor: 4.016

5.  The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.

Authors:  Frederick A Moore; Ernest E Moore; Timothy R Billiar; Yoram Vodovotz; Anirban Banerjee; Lyle L Moldawer
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

Review 6.  Gastrointestinal immune and microbiome changes during parenteral nutrition.

Authors:  Joseph F Pierre
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-02       Impact factor: 4.052

7.  The enteric nervous system neuropeptide, bombesin, reverses innate immune impairments during parenteral nutrition.

Authors:  Rebecca A Busch; Aaron F Heneghan; Joseph F Pierre; Xinying Wang; Kenneth A Kudsk
Journal:  Ann Surg       Date:  2014-09       Impact factor: 12.969

8.  Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats.

Authors:  Xiaowen Liu; Sangita G Murali; Jens J Holst; Denise M Ney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-09-23       Impact factor: 3.619

9.  Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.

Authors:  Martin H Holtmann; Frank Krummenauer; Christina Claas; Kristina Kremeyer; Dirk Lorenz; Olivia Rainer; Iris Vogel; Ulrich Böcker; Stephan Böhm; Carsten Büning; Rainer Duchmann; Guido Gerken; Hans Herfarth; Norbert Lügering; Wolfgang Kruis; Max Reinshagen; Jan Schmidt; Andreas Stallmach; Jürgen Stein; Andreas Sturm; Peter R Galle; Daan W Hommes; Geert D'Haens; Paul Rutgeerts; Markus F Neurath
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

10.  Cranberry proanthocyanidins improve intestinal sIgA during elemental enteral nutrition.

Authors:  Joseph F Pierre; Aaron F Heneghan; Rodrigo P Feliciano; Dhanansayan Shanmuganayagam; Christian G Krueger; Jess D Reed; Kenneth A Kudsk
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-01-28       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.